Literature DB >> 17111081

Usefulness of an immunochromatographical assay, PSA Rapid Test as a primary screening test for prostate cancer.

Kazushi Shigeno1, Naoko Arichi, Tatsuaki Yoneda, Hirofumi Kishi, Hiroaki Shiina, Mikio Igawa.   

Abstract

BACKGROUND: The recent rapid increase of mass screening for prostate cancer by measuring PSA in Japan will increase the economic burden to the healthcare system. PSA Rapid Test (PRT) is a simple inexpensive test. The usefulness of PRT as a primary screening test for prostate cancer was evaluated.
METHODS: When we conducted educational lectures for prostate cancer in our city, screening for prostate cancer using PRT was offered to the male participants. The results of the tests were handed to participants in writing at the end of the lectures. When the results were judged as positive, letters of referral to our institute were enclosed.
RESULTS: One hundred and fourteen (18.6%) of 614 men were judged as positive by PRT. Of the 114 men with positive PRT, 73 (64%) visited our institution. Finally, 37 men underwent a transrectal prostate biopsy and a diagnosis of prostate cancer was made in 21 men (3.4% of all participants). The total costs for the PSA tests in this study were summed to be approximately $2,300, while they would be approximately $9,200 if all participants had undergone screening using the conventional quantitative method from the outset.
CONCLUSION: PRT is a low-cost method to detect patients with prostate cancer. We believe the PRT is useful as an initial screening test for detecting prostate cancer and that the combination of the PRT and more precise quantitative testing would be a reasonable way to reduce the cost and achieve high detection rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17111081     DOI: 10.1007/s11255-006-0086-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection.

Authors:  J B Rietbergen; R Kranse; W J Kirkels; H J De Koning; F H Schröder
Journal:  Br J Urol       Date:  1997-04

2.  [The result of mass screening of 1997 for prostatic cancer in Isesaki City].

Authors:  M Kobayashi; Y Takezawa; S Nakata; M Inoue; H Kurihara; T Kondo; N Kosaku; K Matsumoto; H Nakazato; H Yamanaka
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  2000-01

Review 3.  Prostate-specific antigen.

Authors:  M K Brawer
Journal:  Semin Surg Oncol       Date:  2000 Jan-Feb

4.  ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.

Authors:  C Stephan; K Jung; B Brux; M Lein; P Sinha; D Schnorr; S A Loening
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

5.  Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system.

Authors:  K Uchida; H Takeshima; H Akaza; Y Ono
Journal:  Jpn J Clin Oncol       Date:  2000-02       Impact factor: 3.019

6.  [Mass screening for prostate cancer in Tokushima City: the results of 2001].

Authors:  Hiro-omi Kanayama; Susumu Kagawa; Masato Utsunomiya; Shu Kawashima; Ichiro Takehisa; Haruo Sumitani; Hideaki Yokozeki
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  2004-03

7.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

  7 in total
  1 in total

1.  Evaluation of a rapid one-step PSA test for primary prostate cancer screening.

Authors:  Shingo Ashida; Ichiro Yamasaki; Chiaki Kawada; Hideo Fukuhara; Satoshi Fukata; Kenji Tamura; Takashi Karashima; Keiji Inoue; Taro Shuin
Journal:  BMC Urol       Date:  2021-09-27       Impact factor: 2.264

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.